VRDN:NASDAQ, Viridian Therapeutics, Inc.

VRDN stock overview

Viridian Therapeutics, Inc. (VRDN:NASDAQ) closed at $22.37 on October 23, 2026, down 1.97% on the day. The stock trades 34.8% below its 52-week high of $34.29 and 69.7% above its 52-week low of $13.18. Over the past year, it gained 0.9%. Viridian Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price
$22.37
Day change
-1.97%
Volume
1,175,809
Average volume
1,790,903
Market cap
2B+
52-week range
$13.18 – $34.29
50-day average
$21.59
200-day average
$21.99

Price action over the past year

In 252 trading sessions since October 23, 2025, VRDN closed higher on 123 days (49%). Its best day was May 5, 2026 (+33.36%) and its worst was March 30, 2026 (-32.35%). The stock moved 10% or more in a single session 5 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

VRDN news

About Viridian Therapeutics, Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Similar stocks

Find more stocks like VRDN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.